MARKET

ENSC

ENSC

Ensysce Biosciences Inc
NASDAQ
0.3485
-0.0502
-12.59%
After Hours: 0.3601 +0.0116 +3.33% 18:03 08/13 EDT
OPEN
0.3800
PREV CLOSE
0.3987
HIGH
0.3821
LOW
0.3306
VOLUME
2.69M
TURNOVER
--
52 WEEK HIGH
2.750
52 WEEK LOW
0.2300
MARKET CAP
5.35M
P/E (TTM)
-0.1043
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5h ago
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Barchart · 6h ago
Weekly Report: what happened at ENSC last week (0803-0807)?
Weekly Report · 3d ago
Top Biotech Gainers: CELZ Soars On Patent News, BRVE Debuts Strong, IOVA Revenue Climbs 66%
NASDAQ · 6d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 08/06 17:06
Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings
Benzinga · 08/06 13:43
Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio
TipRanks · 08/06 12:55
Ensysce Biosciences Completes Acquisition Of Cy Biopharma, Secures $17.1M Cash Financing And $21.5M Series C Preferred Stock Private Placement With Potential $38.6M Follow-On Tranche To Fund CY200 Development Through 2028
Benzinga · 08/06 12:06
More
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. It develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases. It is also developing novel neuroplastogenic therapies for complex regional pain syndrome.

Webull offers Ensysce Biosciences Inc stock information, including NASDAQ: ENSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENSC stock methods without spending real money on the virtual paper trading platform.